45.85
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Will Kymera Therapeutics Inc. stock benefit from AI tech trendsOutstanding trading profits - jammulinksnews.com
What drives Kymera Therapeutics Inc. stock priceDouble-digit growth - Autocar Professional
Is Kymera Therapeutics Inc. a good long term investmentFree Stock Market Query - Autocar Professional
What analysts say about Kymera Therapeutics Inc. stockHigh-profit stock alerts - jammulinksnews.com
Kymera Therapeutics Inc. Stock Analysis and ForecastExplosive capital appreciation - jammulinksnews.com
What makes Kymera Therapeutics Inc. stock price move sharplyAlpha Stock Ideas - beatles.ru
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? - Yahoo Finance
Goldman Sachs Initiates Coverage on Kymera Therapeutics as Early-Stage Biotech with Potential Upside of 33.75% - AInvest
How Kymera Therapeutics Inc. stock performs during market volatilityFree Risk Assessment Services - Newser
Forecasting the Future: Targeted Protein Degradation - openPR.com
Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating - Insider Monkey
Kymera Therapeutics shares fall 1.26% intraday amid Gilead Sciences' clinical hold on HIV treatment trials. - AInvest
Kymera Therapeutics stock price target lowered to $65 at Brookline Capital - Investing.com Canada
(KYMR) Investment Analysis - news.stocktradersdaily.com
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN
Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion - Investing.com Canada
Kymera Therapeutics (KYMR) director group buys $13.9 million in stock By Investing.com - Investing.com South Africa
Kymera Therapeutics: Baker Bros acquire $28.8m in shares By Investing.com - Investing.com South Africa
Kymera Therapeutics: Baker Bros acquire $28.8m in shares - Investing.com
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer - MSN
Oppenheimer Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus
Oppenheimer Adjusts Price Target for Kymera Therapeutics (KYMR) - GuruFocus
KYMR: Key Insights on Recent Developments | KYMR Stock News - GuruFocus
Nuclear stocks, Kymera Therapeutics, Estee Lauder - TradingView
Gilead and Kymera in pact to develop cancer drugs - MSN
Kymera Therapeutics (KYMR) Target Price Lowered by Wells Fargo | KYMR Stock News - GuruFocus
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update - TradingView
Kymera Therapeutics launches $250 million public stock offering - Investing.com
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics - PharmaLive
Gilead (GILD) Enters Agreement with Kymera to Enhance Cancer Tre - GuruFocus
Kymera Therapeutics (KYMR) Advances IRAK4 Partnership with Sanofi | KYMR Stock News - GuruFocus
Gilead and Kymera in pact to develop cancer drugs (GILD) (KYMR) - Seeking Alpha
Gilead (GILD) Enters Agreement with Kymera for Novel Cancer Trea - GuruFocus
When (KYMR) Moves Investors should Listen - news.stocktradersdaily.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):